Staff Software Engineer, Platform & Infrastructure
Qualified.com- Full Time
- Expert & Leadership (9+ years)
Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. Freenome utilizes a multiomics platform that combines tumor and non-tumor signals with machine learning to detect cancer in its earliest, most-treatable stages.
Founded in 2014, Freenome has over 500 employees and is growing to match its ambitions to provide access to better screening and earlier cancer detection. Freenome aims to impact patients by empowering everyone to prevent, detect, and treat their disease. This, together with its high-performing culture of respect and cross-collaboration, motivates the team to make every day count.
Become a Freenomer: A “Freenomer” is a determined, mission-driven, results-oriented employee fueled by the opportunity to change the landscape of cancer and make a positive impact on patients’ lives. Freenomers bring their diverse experience, expertise, and personal perspective to solve problems and push to achieve what’s possible, one breakthrough at a time.
Freenome is seeking an experienced infrastructure engineer to help build a cloud-native machine learning platform for the world’s largest multi-analyte cancer genomics dataset.
As an engineering-forward biotech company, Freenome applies modern engineering practices to build reliable, maintainable, scalable, and secure production systems for its clinical lab and Computational and Molecular Research Scientists.
The infrastructure team is a small group where you will help set the culture and build the systems that allow the company to move fast without breaking things. This is an opportunity to do meaningful engineering work that will directly save lives.
The role reports to the Director, Cloud Infrastructure.
Execution Excellence:
Biotechnology company for early cancer detection
Freenome focuses on improving cancer detection through advanced blood tests. The company uses a multiomics approach, analyzing various biological data types, including genomics and proteomics, to find cancer markers in blood samples. This method allows for non-invasive early detection of cancer, which is crucial for effective treatment. Freenome differentiates itself from competitors by its unique combination of data analysis techniques and its commitment to clinical trials and research collaborations. The company's goal is to enhance cancer diagnostics and make early detection accessible to healthcare providers and patients, ultimately aiming to save lives through timely intervention.